Enhanced Recovery After Surgery

Phase 3Small molecule

AAga Khan University

Enhanced Recovery After Surgery is one of 7 small molecule programs targeting Laparoscopic. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LaparoscopicRecruiting

LaparoscopicPhase 3

Recruiting

Competition

Competitive Landscape

8 competitors in Laparoscopic

#DrugCompanyPhaseTrials

Tylenol

KKenvue Brands

Approved

2 2

Advil

KKenvue Brands

Approved

1 3

Anerem

AAcacia Pharma Ltd

Approved

1 4

Enhanced Recovery After Surgery

AAga Khan University

Phase 3

1 5

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 6

Bupivacain

IIstanbul University

Preclinical

2 7

Curare

UUniversity Hospital, Montpellier

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Laparoscopic

NCT07116564

Clinical

Trials by Indication[1]

Laparoscopic1 trial

Impact of ERAS Protocol on Length of Hospital Stay After Laparoscopic Surgeries

Recruiting·—·Phase 4·NCT07116564·98 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Enhanced Recovery After Surgery. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Enhanced Recovery After Surgery compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Enhanced Recovery After Surgery. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aga Khan University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAga Khan University

Enhanced Recovery After Surgery

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Laparoscopic1 trial

References

Drug Info

Quick Facts

Related News